Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Upstream Bio Inc (UPB)

Upstream Bio Inc (UPB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Upstream Bio Inc 890 Winter Street Suite 200 Waltham MA 02451 USA

www.upstreambio.com Employees: 52 P: 781-208-2466

Sector:

Medical

Description:

Upstream Bio Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in development which targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio Inc. is based in WALTHAM, Mass.

Key Statistics

Overview:

Market Capitalization, $K 413,939
Enterprise Value, $K 88,049
Shares Outstanding, K 54,039
Float, K 46,711
% Float 86.44%
Short Interest, K 3,530
Short Float 6.53%
Days to Cover 1.52
Short Volume Ratio 0.52
% of Insider Shareholders 13.56%

Financials:

Annual Sales, $ 2,370 K
Annual Net Income, $ -62,810 K
Last Quarter Sales, $ 680 K
Last Quarter Net Income, $ -33,750 K
EBIT, $ -140,510 K
EBITDA, $ -142,080 K

Growth:

1-Year Return -9.84%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.63 on 11/05/25
Next Earnings Date 03/11/26 [--]
Earnings Per Share ttm -1.88
EPS Growth vs. Prev Qtr 14.86%
EPS Growth vs. Prev Year 90.95%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

UPB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -28.71%
Return-on-Assets % -27.94%
Profit Margin % -2,650.21%
Debt/Equity 0.00
Price/Sales 155.50
Price/Cash Flow N/A
Price/Book 1.09
Book Value/Share 7.02
Interest Coverage -2.66
60-Month Beta 2.96
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar